LigaChem Biosciences to host R&D DAY, unveils 2030 business 메이저 바카라 roadmap

[by Ji, Yong Jun] LigaChem Biosciences (hereinafter referred to as LCB) announced on June 26 that it will host 'LigaChemBio Global 메이저 바카라amp;D DAY 2025' in Yeouido, Seoul, on July 1.

The event will serve as a platform for LCB to present its current 메이저 바카라amp;D status and mid- to long-term strategic plans to key stakeholders, including investors, analysts, and media representatives. It will also highlight the company's globally competitive antibody-drug conjugate (ADC) technology and its broader business vision. To engage both Korean and international investors and ADC experts, the event will be live-streamed on YouTube in both Korean and English.

The first part of the event will feature an analysis of the scalability of ADC technology, along with a presentation detailing how LCB's platform technology is differentiated in terms of clinical strategy. In addition, the session will include updates on the global clinical 메이저 바카라 status of core pipelines such as HER2-ADC and ROR1-ADC, real-world application cases, interim results of Phase 1 clinical trials, and future 메이저 바카라 plans.

The second part of the event will center on next-generation ADC technologies and innovation in the field of immuno-oncology. This session will introduce a range of innovative candidates currently under development while also highlighting the distinctiveness of recently acquired targets and outlining the company’s strategic plans for expanding its technological platform into the immuno-oncology sector.

In the final session, LCB will outline its global 메이저 바카라 strategy and long-term growth vision. This will include detailed plans for technology transfer aimed at expanding international partnerships, as well as a mid- to long-term 메이저 바카라 roadmap and key growth drivers through 2030. Each presentation will be followed by an in-depth Q&A session, fostering direct discussion with attendees.

LCB is actively advancing the 메이저 바카라 of next-generation ADCs through its proprietary ConjuALL platform technology, with multiple pipeline candidates having already progressed into clinical stages.

"Through Global R&D DAY, we aim to comprehensively showcase the distinct competitiveness of our ADC technology, our strategic expansion into the immuno-oncology field, and our approach to forming global partnerships. This event will serve to further concretize our vision of becoming a leading company in the development of next-generation anticancer treatments," an LCB official emphasized.